17 October 2013 08:43 [Source: ICIS news]
SINGAPORE (ICIS)--Roche’s group sales rose by 3% year on year to Swiss francs (Swfr) 34.9bn ($38.4bn) in the first nine months of this year, supported by strong demand for its breast cancer treatments, the Swiss pharmaceuticals firm said on Thursday.
At constant exchange rate, the company’s group sales rose by 6% in January-September this year, it said in a statement.
“Demand for our products has remained strong in both divisions [pharmaceuticals and diagnostics]. We will meet our full-year targets,” Roche CEO Severin Schwan said.
The company expects its group sales to increase in line the growth seen last year at constant exchange rates.
($1 = Swfr0.91)
|ICIS news FREE TRIAL|
|Get access to breaking chemical news as it happens.|
|ICIS Global Petrochemical Index (IPEX)|
Asian Chemical Connections